<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587363</url>
  </required_header>
  <id_info>
    <org_study_id>CR108483</org_study_id>
    <secondary_id>2018-001104-11</secondary_id>
    <secondary_id>42756493EDI1008</secondary_id>
    <nct_id>NCT03587363</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to characterize the single dose pharmacokinetic of
      erdafitinib in participants with impaired hepatic function relative to participants with
      normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2018</start_date>
  <completion_date type="Anticipated">December 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Tmax is the time to reach maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-Time Curve (AUC)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>AUC is area under plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (t1/2term, Lambda)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>t1/2term, Lambda is elimination half-life associated with the terminal slope (Lambda[Z]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/Lambda(Z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Plasma Clearance (CL/F)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>CL/F is total plasma clearance of drug after extravascular administration, uncorrected for absolute bioavailability (BA), calculated as Dose/AUC (0-infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Vd/F is apparent volume of distribution after extravascular administration, uncorrected for absolute BA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Approximately 50 days</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily have a causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erdafitinib</intervention_name>
    <description>Participants will receive 6 mg (2*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.</description>
    <arm_group_label>Cohort 1: Normal Hepatic Function</arm_group_label>
    <arm_group_label>Cohort 2: Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Cohort 3: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Cohort 4: Severe Hepatic Impairment</arm_group_label>
    <other_name>JNJ-42756493</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman must have a clinically stable hepatic function as confirmed by the serum
             bilirubin and transaminase levels measured during screening and those measured on Day
             -1

          -  If a woman (a) must not be of childbearing potential postmenopausal or surgically
             sterile (b) must agree to not donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for 3 months after the study drug administration

          -  If a woman who is considered surgically sterile but not postmenopausal, must have a
             negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at
             screening (exemptions: pregnancy test not required in female participants with prior
             hysterectomy or prior bilateral oophorectomy)

          -  If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for 3 months after the study drug administration

          -  Participants with hepatic impairment must meet the Child-pug classification for mild,
             moderate or severe hepatic impairment and must have stable hepatic function

        Exclusion Criteria:

          -  History or current evidence of ophthalmic disorder, such as central serous retinopathy
             (CSR) or retinal vein occlusion, active wet age related macular degeneration, diabetic
             retinopathy with macular edema, uncontrolled glaucoma, corneal pathology such as
             keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or
             ulceration

          -  Any surgical or medical condition that may alter the absorption, metabolism, or
             excretion of the study drug (example, gastrectomy, Crohn's disease etc), with the
             exception of hepatic impairment

          -  History of drug abuse according to Diagnostic and Statistical Manual of Mental
             Disorders (5th edition) (DSM-V) criteria within 6 months before screening or positive
             test result(s) for drugs of abuse (including barbiturates, opiates, cocaine,
             cannabinoids, amphetamines, hallucinogens, and benzodiazepines) at screening and on
             Day -1

          -  Known allergy to the study drug or any of the excipients of the formulation (Physical
             Description of Study Drug[s], for a list of excipients)

          -  Donated blood or blood products or had substantial loss of blood (more than 500
             milliliter [mL]) within 3 months before study drug administration or intention to
             donate blood or blood products during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108483</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

